JP2020512368A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512368A5
JP2020512368A5 JP2019553442A JP2019553442A JP2020512368A5 JP 2020512368 A5 JP2020512368 A5 JP 2020512368A5 JP 2019553442 A JP2019553442 A JP 2019553442A JP 2019553442 A JP2019553442 A JP 2019553442A JP 2020512368 A5 JP2020512368 A5 JP 2020512368A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
composition according
synuclein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019553442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/052236 external-priority patent/WO2018178950A1/en
Publication of JP2020512368A publication Critical patent/JP2020512368A/ja
Publication of JP2020512368A5 publication Critical patent/JP2020512368A5/ja
Withdrawn legal-status Critical Current

Links

JP2019553442A 2017-03-31 2018-03-30 シヌクレイノパチーを治療するための組成物及び方法 Withdrawn JP2020512368A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US62/479,818 2017-03-31
US201762528790P 2017-07-05 2017-07-05
US62/528,790 2017-07-05
PCT/IB2018/052236 WO2018178950A1 (en) 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies

Publications (2)

Publication Number Publication Date
JP2020512368A JP2020512368A (ja) 2020-04-23
JP2020512368A5 true JP2020512368A5 (cg-RX-API-DMAC7.html) 2021-05-06

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553442A Withdrawn JP2020512368A (ja) 2017-03-31 2018-03-30 シヌクレイノパチーを治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US20200377579A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630815A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020512368A (cg-RX-API-DMAC7.html)
KR (1) KR20200026789A (cg-RX-API-DMAC7.html)
CN (1) CN110997715A (cg-RX-API-DMAC7.html)
AU (1) AU2018242626A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058304A1 (cg-RX-API-DMAC7.html)
IL (1) IL269637A (cg-RX-API-DMAC7.html)
JO (1) JOP20190227A1 (cg-RX-API-DMAC7.html)
MA (1) MA48730A (cg-RX-API-DMAC7.html)
SG (1) SG11201908672WA (cg-RX-API-DMAC7.html)
WO (1) WO2018178950A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
MX2022006676A (es) * 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
TW202227131A (zh) 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
JP2026506882A (ja) * 2023-02-06 2026-02-27 クリエイティブ バイオ-ぺプタイズ インコーポレイテッド 神経学的障害を処置するためのペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HRP20150831T1 (hr) * 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
PL2723379T3 (pl) * 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн

Similar Documents

Publication Publication Date Title
JP7725185B2 (ja) 抗trem2抗体及びその使用方法
JP2023029882A (ja) 抗trem2抗体及びその使用方法
JP2020141669A5 (cg-RX-API-DMAC7.html)
JP2019517540A5 (cg-RX-API-DMAC7.html)
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2019527194A5 (cg-RX-API-DMAC7.html)
CN114558129A (zh) 用于降低心血管风险的方法
HK1244229A1 (zh) 治疗CROHN病的整联蛋白β7拮抗剂和方法
JP2013538796A5 (cg-RX-API-DMAC7.html)
JP2022517441A (ja) Btla抗体
JP2018501197A5 (cg-RX-API-DMAC7.html)
US12116407B2 (en) Methods of treating neurodegenerative diseases
JP2018526330A5 (cg-RX-API-DMAC7.html)
JP2019503706A5 (cg-RX-API-DMAC7.html)
JP2018516933A (ja) 抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法
JP2020527152A5 (cg-RX-API-DMAC7.html)
JP2020505350A5 (cg-RX-API-DMAC7.html)
US20230287133A1 (en) Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
JP2022512346A5 (cg-RX-API-DMAC7.html)
CA3199806A1 (en) Methods of reducing tau in human subjects
S. Rommer et al. Monoclonal antibodies in the treatment of neuroimmunological diseases
JP2024526742A5 (cg-RX-API-DMAC7.html)
JP2021516702A (ja) 抗−vegfr−2抗体
HK40119132A (en) Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
HK40056920A (en) Integrin beta7 antagonists and methods of treating crohn's disease